410 related articles for article (PubMed ID: 32779815)
1. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19.
Peña-Silva R; Duffull SB; Steer AC; Jaramillo-Rincon SX; Gwee A; Zhu X
Br J Clin Pharmacol; 2021 Mar; 87(3):1589-1590. PubMed ID: 32779815
[No Abstract] [Full Text] [Related]
2. Repositioning Ivermectin for Covid-19 treatment: Molecular mechanisms of action against SARS-CoV-2 replication.
Low ZY; Yip AJW; Lal SK
Biochim Biophys Acta Mol Basis Dis; 2022 Feb; 1868(2):166294. PubMed ID: 34687900
[TBL] [Abstract][Full Text] [Related]
3. High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
Buonfrate D; Chesini F; Martini D; Roncaglioni MC; Ojeda Fernandez ML; Alvisi MF; De Simone I; Rulli E; Nobili A; Casalini G; Antinori S; Gobbi M; Campoli C; Deiana M; Pomari E; Lunardi G; Tessari R; Bisoffi Z
Int J Antimicrob Agents; 2022 Feb; 59(2):106516. PubMed ID: 34999239
[TBL] [Abstract][Full Text] [Related]
4. The Repurposing of Ivermectin for Malaria: A Prospective Pharmacokinetics-Based Virtual Clinical Trials Assessment of Dosing Regimen Options.
Badhan R; Zakaria Z; Olafuyi O
J Pharm Sci; 2018 Aug; 107(8):2236-2250. PubMed ID: 29626533
[TBL] [Abstract][Full Text] [Related]
5. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
Rakedzon S; Neuberger A; Domb AJ; Petersiel N; Schwartz E
J Travel Med; 2021 Feb; 28(2):. PubMed ID: 33480414
[TBL] [Abstract][Full Text] [Related]
6. Repurposing the drug, ivermectin, in COVID-19: toxicological points of view.
Shirazi FM; Mirzaei R; Nakhaee S; Nejatian A; Ghafari S; Mehrpour O
Eur J Med Res; 2022 Feb; 27(1):21. PubMed ID: 35123559
[TBL] [Abstract][Full Text] [Related]
7. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
Wehbe Z; Wehbe M; Iratni R; Pintus G; Zaraket H; Yassine HM; Eid AH
Front Immunol; 2021; 12():663586. PubMed ID: 33859652
[TBL] [Abstract][Full Text] [Related]
8. Ivermectin in COVID-19: What do we know?
Pandey S; Pathak SK; Pandey A; Salunke AA; Chawla J; Sharma A; Sharma S; Thivari P; Ratna HVK
Diabetes Metab Syndr; 2020; 14(6):1921-1922. PubMed ID: 33032231
[No Abstract] [Full Text] [Related]
9. Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin.
Marty FM; Lowry CM; Rodriguez M; Milner DA; Pieciak WS; Sinha A; Fleckenstein L; Baden LR
Clin Infect Dis; 2005 Jul; 41(1):e5-8. PubMed ID: 15937753
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
11. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA; Wagstaff KM
Biochem Biophys Res Commun; 2021 Jan; 538():163-172. PubMed ID: 33341233
[TBL] [Abstract][Full Text] [Related]
12. The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable.
Lawrence JM; Meyerowitz-Katz G; Heathers JAJ; Brown NJL; Sheldrick KA
Nat Med; 2021 Nov; 27(11):1853-1854. PubMed ID: 34552263
[No Abstract] [Full Text] [Related]
13. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
Roche D; O'Connor C; Murphy M
Clin Exp Dermatol; 2021 Oct; 46(7):1327-1328. PubMed ID: 33896010
[No Abstract] [Full Text] [Related]
14. Intensive Treatment With Ivermectin and Iota-Carrageenan as Pre-exposure Prophylaxis for COVID-19 in Health Care Workers From Tucuman, Argentina.
Chahla RE; Medina Ruiz L; Ortega ES; Morales Rn MF; Barreiro F; George A; Mancilla Rn C; D' Amato Rn S; Barrenechea G; Goroso DG; Peral de Bruno M
Am J Ther; 2021 Aug; 28(5):e601-e604. PubMed ID: 34491960
[No Abstract] [Full Text] [Related]
15. Inhaled route and anti-inflammatory action of ivermectin: Do they hold promise in fighting against COVID-19?
Mittal N; Mittal R
Med Hypotheses; 2021 Jan; 146():110364. PubMed ID: 33246694
[TBL] [Abstract][Full Text] [Related]
16. Development of a Minimal Physiologically-Based Pharmacokinetic Model to Simulate Lung Exposure in Humans Following Oral Administration of Ivermectin for COVID-19 Drug Repurposing.
Jermain B; Hanafin PO; Cao Y; Lifschitz A; Lanusse C; Rao GG
J Pharm Sci; 2020 Dec; 109(12):3574-3578. PubMed ID: 32891630
[TBL] [Abstract][Full Text] [Related]
17. Pandemic and promise: progress towards finding an effective treatment for Novel Coronavirus 19.
Merone L; Finlay S
Aust N Z J Public Health; 2020 Dec; 44(6):437-439. PubMed ID: 33044799
[No Abstract] [Full Text] [Related]
18. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
Kinobe RT; Owens L
Fundam Clin Pharmacol; 2021 Apr; 35(2):260-276. PubMed ID: 33427370
[TBL] [Abstract][Full Text] [Related]
19. Repurposing of host-based therapeutic agents for the treatment of coronavirus disease 2019 (COVID-19): a link between antiviral and anticancer mechanisms?
Alonso DF; Farina HG
Int J Antimicrob Agents; 2020 Sep; 56(3):106125. PubMed ID: 32739476
[No Abstract] [Full Text] [Related]
20. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J; Zoni R; Bangher M; Villamandos S; Bobadilla A; Plano F; Campias C; Chaparro Campias E; Achinelli F; Guglielmone HA; Ojeda J; Medina F; Farizano Salazar D; Andino G; Ruiz Diaz NE; Kawerin P; Meza E; Dellamea S; Aquino A; Flores V; Martemucci CN; Vernengo MM; Martinez SM; Segovia JE; Aguirre MG
Trials; 2020 Nov; 21(1):965. PubMed ID: 33234158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
